Atrial fibrillation in the setting of cardiac amyloidosis - A review of the literature.

Atrial arrhythmias Atrial fibrillation Cardiac amyloidosis Catheter ablation

Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
31 Mar 2024
Historique:
received: 30 01 2024
revised: 18 03 2024
accepted: 22 03 2024
medline: 3 4 2024
pubmed: 3 4 2024
entrez: 2 4 2024
Statut: aheadofprint

Résumé

Cardiac amyloidosis (CA) is related to the aggregation of insoluble fibrous deposits of misfolded proteins within the myocardium. Transthyretin amyloidosis (ATTR) and immunoglobulin light-chain amyloidosis are the main forms of CA. Atrial fibrillation (AF) is a common arrhythmia in CA patients, especially in those with ATTR amyloidosis. Increased atrial preload and afterload, atrial enlargement, enhanced atrial wall stress, and autonomic dysfunction are the main mechanisms of AF in CA patients. CA is associated with the formation of endocardial thrombi and systemic embolism. The promoters of thrombogenesis include endomyocardial damage, blood stasis, and hypercoagulability. The prevalence of thrombi in patients with AF remains elevated despite long-term anticoagulation. Consequently, transesophageal ultrasound examinations before cardioversion should be performed to exclude endocardiac thrombi despite anticoagulation. Furthermore, the CHA

Identifiants

pubmed: 38565394
pii: S0914-5087(24)00053-4
doi: 10.1016/j.jjcc.2024.03.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Conflicts of interest None.

Auteurs

George Bazoukis (G)

Department of Cardiology, Larnaca General Hospital, Larnaca, Cyprus; European University Cyprus, School of Medicine, Nicosia, Cyprus. Electronic address: gbazoykis@yahoo.gr.

Athanasios Saplaouras (A)

Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.

Polyxeni Efthymiou (P)

Department of Cardiology, Larnaca General Hospital, Larnaca, Cyprus.

Andronicos Yiannikourides (A)

Department of Cardiology, Larnaca General Hospital, Larnaca, Cyprus.

Tong Liu (T)

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.

Dimitrios Sfairopoulos (D)

First Department of Cardiology, University of Ioannina Medical School, Ioannina, Greece.

Panagiotis Korantzopoulos (P)

First Department of Cardiology, University of Ioannina Medical School, Ioannina, Greece.

Dimitrios Varrias (D)

Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

Konstantinos P Letsas (KP)

Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.

Costas Thomopoulos (C)

Department of Cardiology, General Hospital of Athens "Laiko", Athens, Greece.

Gary Tse (G)

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China; Kent and Medway Medical School, University of Kent and Canterbury Christ Church University, Canterbury, Kent, UK; School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China.

Stavros Stavrakis (S)

Department of Medicine, Cardiovascular Section, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.

Classifications MeSH